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Background: The positive transcription elongation factor b (P-TEFb) plays an essential role in activating HIV genome
transcription. It is recruited to the HIV LTR promoter through an interaction between the Tat viral protein and its Cyclin
T1 subunit. P-TEFb activity is inhibited by direct binding of its subunit Cyclin T (1 or 2) with Hexim (1 or 2), a cellular
protein, bound to the 7SK small nuclear RNA. Hexim1 competes with Tat for P-TEFb binding.
Results: Mutations that impair human Cyclin T1/Hexim1 interaction were searched using systematic mutagenesis of
these proteins coupled with a yeast two-hybrid screen for loss of protein interaction. Evolutionary conserved Hexim1
residues belonging to an unstructured peptide located N-terminal of the dimerization domain, were found to be
critical for P-TEFb binding. Random mutagenesis of the N-terminal region of Cyclin T1 provided identification of
single amino-acid mutations that impair Hexim1 binding in human cells. Furthermore, conservation of critical
residues supported the existence of a functional Hexim1 homologue in nematodes.
Conclusions: Single Cyclin T1 amino-acid mutations that impair Hexim1 binding are located on a groove between the
two cyclin folds and define a surface overlapping the HIV-1 Tat protein binding surface. One residue, Y175, in the centre
of this groove was identified as essential for both Hexim1 and Tat binding to P-TEFb as well as for HIV transcription.
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Transcription of most class II genes stops shortly after
initiation because RNA polymerase II (RNAPII) is arrested
by negative elongation factors (NELF, DSIF). Phosphor-
ylation by the positive transcription elongation factor
(P-TEFb) is required to counteract their effect and resume
a productive transcription elongation [1]. In particular,
recruitment of P-TEFb to the early transcription elong-
ation complex is a critical step for productive HIV genome
expression [2]. This recruitment relies on P-TEFb associ-
ation with the Tat viral protein bound to the TAR domain
of the nascent transcript and results in phosphorylation
of the Negative Elongation Factors, NELF and DSIF,
that prevent elongation of transcription. P-TEFb next
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unless otherwise stated.(CTD) and might thus contribute to recruit splicing,
cleavage and polyadenylation factors for co-transcriptional
pre-mRNA processing [3]. Core P-TEFb comprises a
kinase, Cdk9, and a Cyclin T (CycT1 or CycT2). A cellular
feed-back loop involving the 7SK small nuclear RNA regu-
lates the activity of P-TEFb [4,5]. In vivo, 7SK snRNA forms
a core complex with the MePCE and Larp7 proteins [6].
This core 7SK snRNP complex binds the Hexim1 protein
and the Hexim1/7SK snRNP in turn contacts CycT1 and
inactivates P-TEFb [7-10]. Hexim1 competes with Tat for
P-TEFb binding and represses Tat transactivation of HIV
transcription [11]. The equilibrium between active and
inactive cellular P-TEFb complexes is highly regulated.
Following transcriptional arrest, 7SK RNA is trapped by
heterogeneous nuclear ribonucleoproteins (hnRNPs), resul-
ting in release of Hexim1 and increased P-TEFb activity
[12-14]. Such release might be assisted by interactions with
Brd4 [15-17], JMJD6 [18] and Tat [19,20]. Partial 3-Dral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[24,25] have been established by X-ray crystallography or
NMR. Nevertheless, little is known on how these compo-
nents assemble together. To tackle these questions, an
extensive single amino-acid mutagenesis of human Hexim1
and Cyclin T1 residues was performed. Mutants deficient
in Hexim1/Cyclin T1 binding were screened by yeast two-
hybrid. Combined with 3-D structures obtained by NMR
or X-ray crystallography, such strategy determines surface
residues involved in protein/protein interactions [26].
Results
Randomly generated Cyclin T1 mutations screened by
reverse two-hybrid
The ability of Hexim1 proteins to directly bind Cyclin T1
was assayed in a yeast two-hybrid assay in cells where the
ura3 gene is placed under the control of GAL4 regulatory
sequences [7]. Cells expressing wild-type Cyclin T1 and
wild-type Hexim1 fused to the GAL4 DNA-binding
and activation domains respectively grew in a selective
medium lacking uracil (LTU), thereby demonstrating a
contact between both proteins. 7SK RNA is not required
for Cyclin T1/Hexim1 interaction in this test [8]. Consist-
ently, the “ILAA” Hexim1 mutant that is deficient in 7SK
RNA binding interacts with Cyclin T1.
To identify Cyclin T1 residues that are required for
Hexim1 binding, we used random mutagenesis by error-
prone PCR followed by a reverse two-hybrid screen in
yeast [26,27]. The 5-step procedure was restricted to the
260 N-terminal amino-acids of Cyclin T1 corresponding
to the Cyclin Box Domain (CBD) since a previous study
had indicated that it comprised the Hexim1 binding
sequences [7]. A mutant Cyclin T1 library was generated
by PCR amplification of the CBD using error-prone
conditions to introduce randomly dispersed mutations
(step 1a). In parallel, the CBD sequence was excised
from the Gal4BD-CycT1 plasmid by restriction (step 1b).
Yeast cells containing the ura3 gene under the control
of Gal4 promoter were co-transformed with Gal4AD-
Hexim1, excised Gal4BD-CycT1 plasmids and the error-
prone PCR library to allow homologous recombination
of Gal4BD-CycT1 in yeast (step 2). 5-FOA is toxic to
yeast when the ura3-encoded enzyme is expressed and
was used as a counter-selective drug. Thus, Cyclin T1
mutations or truncations that prevented Hexim1 binding
to Cyclin T1 allowed transformed cells to survive in the
presence of 5-FOA. These colonies were selected (step 3)
and DNA fragments of the Cyclin T1 CBD were amplified
by PCR. Their size was checked by electrophoresis (step
4) and fragments with appropriate size were sequenced
(step 5). Performing random PCR mutagenesis on the
entire Cyclin box (909 bp) often generated multiple
mutations in the same sequence. As multiple mutations
complicate the interpretation, smaller Cyclin T1 fragmentswere amplified by error-prone PCR to increase the yield of
single amino-acid mutations. Four fragments using distinct
sets of primers were amplified by error-prone PCR and
screened independently (Figure 1A). Fragments I, II, III and
IV respectively corresponded to Cyclin T1 residues 1 to
106, 88 to 188, 88 to 261 and 140 to 261.
DNA fragments from 203 colonies were sequenced
(step 5). Among them, 74 had multiple amino-acid changes,
premature stop codons or frame-shifts, 38 had no detectable
amino-acid change and 68 contained a unique amino-acid
mutation. These corresponded to 61 distinct mutations
listed as “Random” of 56 residues scattered along the entire
Cyclin Box Domain (260 amino-acids) (Figure 1A and B). 9
of those residues were found mutated more than once in
the screen suggesting that a significant proportion of the
possible point mutations affecting Hexim1 binding had
been generated.
Cyclin T1 mutations involved in Hexim1 binding
Several mutations were found outside the sequence that
had been amplified by error-prone PCR (Figure 1A). For
instance, the Y175H mutation was obtained once follow-
ing error-prone amplification of fragment “I” which spans
only over residues 1 to 104. Furthermore, many of the 203
sequenced DNA fragments showed no mutation. These
observations called for a validation step. The PCR frag-
ments were cloned back into the starting Gal4BD-CycT1
plasmid. A forward two-hybrid assay (growth on selective
medium lacking uracil) was then used to validate the
loss of Hexim1 binding. Indeed, 30 mutations allowed
growth like the wild-type Cyclin T1 (+++), or just showed
growth impairment (+) and were not further investigated
(Figure 1B). However, 26 out of the initial 61 Cyclin T1
mutants did not grow at all (−) thereby confirming a loss
in Hexim1 binding capacity.
As P-TEFb is a heterodimer composed of Cyclin T1
and Cdk9, we looked for Cyclin T1 mutations that
would not disrupt the Cyclin T1/Cdk9 interaction. Thus,
the 26 Cyclin T1 mutants deficient for Hexim1 binding
were further submitted to a forward yeast two-hybrid
assay for binding to Cdk9. 15 Cyclin T1 mutants deficient
(−) for Hexim binding were either completely (−) or par-
tially (+) impaired for Cdk9 binding as well (Figure 1B).
However, the reverse two-hybrid experiment still provided
10 Cyclin T1 mutants that had lost detectable interaction
with Hexim1 and kept full Cdk9 binding capacity (Hexim
(−), Cdk9 (+++), shown in bold in Figure 1B) and were
kept for further studies. 9 additional such mutants were
generated by targeted mutagenesis as discussed below.
Mutations leading to Hexim1 binding deficiency cluster
along a groove between the cyclin folds
Despite high divergence in amino-acid sequences, Cyclins
share a common conserved cyclin box structure [28].
BA
Figure 1 Cyclin T1 point mutations screened for Hexim1 binding deficiency by yeast two-hybrid. (A) Distribution of Cyclin T1 single mutations
generated by random mutagenesis. Colours mark the sequences that were amplified in four different error-prone PCR reactions: I – from residue 1 to
106 (yellow), II – from 88 to 188 (green), III – from 88 to 261 (cyan) and IV – from 140 to 261 (magenta). The position of single amino-acid mutations
obtained following each PCR are highlighted in black. Several mutations are found outside the PCR amplified sequence. (B) List of Cyclin T1 point
mutations obtained by “Random” or “Targeted” mutagenesis. Numbers in brackets indicate the mutations that occurred more than once. Wild-type
interaction (+++), decreased interaction (+) and lack of interaction (−) are deduced from regular, slow or no growth on LTU selective medium,
respectively. (nd) mutations have not been validated. Mutations leading to complete loss of Hexim1 binding (−) without affecting Cdk9
binding (+++) are shown in bold. Colours indicate the error-prone PCR reactions providing each mutation.
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generated two cyclin folds. When positioned on the Cyclin
T1 3-D structure derived from crystals of P-TEFb [21,22],
many residues essential for Hexim1 binding appeared
clustered on the Cyclin T1 surface along the groove
between the cyclin folds (Figure 2A-D). Mutations of
most these residues kept a normal interaction with Cdk9
(orange and red colours) but some showed a partial
Cdk9 binding deficiency (brown colour). Cyclin T1 resi-
dues such as C200, leading to complete Cdk9 bindingdeficiency were coloured in black and hardly seen on the
surface as they were buried inside the cyclin folds. Fur-
thermore, although Cdk9 interacts mainly with residues
in the N-terminal fold (pale yellow) rather than the C-
terminal fold (pale blue) of Cyclin T1, several mutations
leading to Cdk9 binding deficiency corresponded to resi-
dues in the C-terminal Cyclin fold. Mutation of these resi-
dues likely lead to major twists in the cyclin box structure.
Importantly, several residues that came out in the screen
cluster around tyrosine Y175 that is largely exposed to
Figure 2 (See legend on next page.)
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Figure 2 Positioning of Cyclin T1 mutations on the 3D structure of P-TEFb. (A), (B), (C) and (D) Cyclin T1 mutations were localised on
P-TEFb.ATP (pdb3blq) and (E) and (F) on Tat.P-TEFb.ATP (pdb3MIA) 3D structures. The N-terminal cyclin fold is in pale yellow, the C-terminal one
is in pale cyan and Tat is in pink. Mutations are coloured according to their 2-hybrid interaction phenotype (Figure 1B); in red [Cdk9(+++); Hexim1(−)],
orange [Cdk9(+++); Hexim1(+)], brown [Cdk9(+); Hexim1(−)] and black [Cdk9(−); Hexim1(−)]. Targeted mutagenesis of K168 and D169 provided [Cdk9
(+++); Hexim1(−)] interaction phenotypes. (G) Aromatic residues in the funnel formed by helices in N-terminal and C-terminal Cyclin folds. Position
of Cyclin T1 mutations on helices H1 (yellow), H2 (green), H1′ (cyan) and H2′ (marine) of P-TEFb.ATP (pdb3blq) structure; (H) and (I) H-bond network
linking the cyclin fold helices to Y175 in P-TEFb.ATP (pdb3blq) and Tat.P-TEFb.ATP (pdb3MIA), respectively.
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(Figure 2B). Targeted mutagenesis of K168 and D169
residues which are in close proximity to Y175, provided
two additional mutants of Cyclin T1 that were impaired
for their Hexim1 binding, while efficiently bound Cdk9
(Figure 1B). Noteworthy, the HIV-1 Tat protein binds
human Cyclin T1 in the same groove between the cyclin
folds that is centred around Y175 as shown on the 3-D
structure [22] (Figure 2E and F).
Conserved binding residues in the C. elegans Cyclin T1
and Hexim1 homologues
Regulation of P-TEFb by Hexim1/7SK RNA has been
discovered in human cells and recently described in
Drosophila cells [29]. It has been conserved throughout
evolution at least from mammals to insects. Apart from
one (P85L in human Cyclin T1), mutations disrupting
Hexim1 binding without affecting Cdk9 binding corres-
pond to residues conserved in human Cyclin T1 and
Cyclin T2 as well as in Drosophila Cyclin T (Figure 3A,
highlighted residues). One Cdk9 and two Cyclin T1 ho-
mologues (cit-1.1 and cit-1.2) have been characterized
in C. elegans [30] while a bioinformatic study suggested
that Hexim and 7SK RNA homologues are present in
nematodes [31]. The putative ceHexim shows very weak
sequence homologies with its metazoan counterparts
(Figure 3B). Nevertheless, we found that ceHexim and
cit-1.2 interact in the two-hybrid assay (Figure 4A, lane 3).
Mutations of Y175 abolished human Cyclin T1/Hexim1
interaction in a two-hybrid assay (Figure 1B). Both Y193E
and Y193S mutations of cit-1.2 (corresponding to muta-
tions of Y175 in human Cyclin T1) abolished interaction
with ceHexim (Figure 4A, lanes 5 and 6).
The weak homologies between human and nematode
Hexim proteins concern residues in three small known
important sequences: the basic region involved in 7SK
RNA binding, the PYNT motif and the N-terminus of
the dimerization domain already known to be involved
in Cyclin T binding. A systematic targeted mutagenesis
of conserved residues in the PYNT region and the
dimerization domain of human Hexim1 pointed to
three new residues that impaired Cyclin T1 binding in
a two hybrid assay: F262, F267 and H275 (Figure 4B,
lane 3–5). The F156L mutation of ceHexim (correspond-
ing to F267 mutation in human Hexim) also abolishedceHexim interaction with cit-1.2 in the two-hybrid assay
(Figure 4A, lane 4), thus paralleling with observations in
the human system. These results highlighted the import-
ance of the conserved phenylalanine F267 in Hexim1
and tyrosine Y175 in Cyclin T1 (human nomenclatures).
Moreover, they further support the idea that despite their
limited sequence homology, nematodes have a true Hexim
homologue, interacting with a Cyclin T1 homologue.
Mutations of Y175 impair Cyclin T1 binding to Hexim1 in
human cells
Mutant Gal4BD-CycT1 proteins that had successfully
passed the validating two-hybrid assays [binding to Hexim1
negative (−) and Cdk9 positive (+++)] were next expressed
in mammalian cells. Wild-type Gal4-CycT1 expressed
in 293 cells co-immunoprecipitated CDK9 and Hexim1
(Figure 5A, lanes 1, 11 and 12) like other previously re-
ported fusion Cyclin T1 [32]. However, most of the 14
Hexim1 (−) Cdk9 (+++) mutations tested did not signifi-
cantly alter Hexim1 binding. Only 4 Cyclin T1 mutants
(L133R, K168E, Y175E and Y175S) were reproducibly
impaired in Hexim1 binding relative to Gal4-CycT1
wild-type (lanes 8, 10, 15, 16). The L133R mutant was
reproducibly deficient in Cdk9 binding. Perhaps because
L133 is buried within the N-terminal cyclin fold, close
to the Cdk9 interaction surface. Replacement of leucine
by a charged residue might affect the folding of the
whole domain. In contrast, K168 and Y175 are exposed
to the solvent. K168E, Y175H, Y175S and Y175E mutants
associated Cdk9 as efficiently as the wild-type protein.
The Y175E mutation exhibited the sharpest deficiency in
Hexim1 binding.
To better characterize the Y175E mutation, a CTD-
kinase assay was performed on immunoprecipitates. The
activity of P-TEFb with wild-type Cyclin T1 was enhanced
when RNAse was added to digest 7SK and disrupt Hexim1
interaction [4,5] (Figure 5B, lanes 1,2). In contrast, the
kinase activity of P-TEFb with CyclinT1-Y175E was not
affected by RNAse (lanes 3,4) and was similar to that of
wild type Cyclin T1 after treatment with RNAse.
As an assay for Cyclin T1 mutant function in live cells,
we used an assay that would rely on P-TEFb recruitment.
A luciferase gene transcription was driven by a minimal
HIV promoter, comprising 5 Gal4 binding sites upstream
the TATA box. P-TEFb is recruited to and activates
Figure 3 Conservation of Hexim and Cyclin T proteins. (A) Alignment of Cyclin T amino-acid sequences from Homo sapiens (CycT1 and CycT2);
Drosophila melanogaster (dCycT); Caenorhabditis elegans (cit-1.2). CycT1 residues generated by random mutagenesis that resulted in Hexim1 binding
deficiency are highlighted in black. Numbers above the sequences correspond to the a.a. number in the human Hexim1 and Cyclin T1
sequences respectively. (B) Alignment of Hexim amino-acid sequences from Homo sapiens (HsHEX1 and HsHEX2); Drosophila melanogaster
(DmHEX); Caenorhabditis elegans (CeHEX). Nematode residues conserved in metazoa are highlighted in yellow. Residues highlighted in black
are required for Cyclin T1 binding in a two-hybrid assay.
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fused to the Gal4 DNA binding domain [33,34]. Indeed,
wild type Gal4 Cyclin T1 enhanced luciferase produc-
tion (Figure 5C). Gal4 Cyclin T1s with a mutated Y175
were reproducibly close to two fold more efficient. This
was consistent with their higher CTD kinase activity
and likely due to an escape from repression by Hexim1.
To conclude, we have generated point mutations in Cyc-
lin T1 that strongly suppress Hexim1 binding capacity and
brought stronger P-TEFb activity than wild-type Cyclin T1.
Mutations of Y175 strongly impair Cyclin T1 binding to
HIV Tat
We next investigated the ability of Cyclin T1 mutants to
support Tat dependent transcription from the HIV LTR.
As murine Cyclin T1 cannot support Tat transactivation,
we monitored the rescue of Tat transactivation in 3T3
cells by human HA-Cyclin T1 proteins [35]. Indeed, wild
type HA-Cyclin T1 efficiently rescued Tat transactivation
in murine cells (Figure 6A). In contrast, both Y175E and
Y175S mutant proteins were deficient and did not rescue
Tat transactivation. The available 3D structure of P-TEFb
reveals that tyrosine Y175 is in the middle of the Tat inter-
acting surface on Cyclin T1 [21,22] (Figure 2, compare
2B and 2F). Therefore, we investigated the capacity of
HA-Cyclin T1 proteins to associate Flag-Tat in human
cells. Indeed, Flag-Tat associated with the wild type
HA-Cyclin T1 (Figure 6B). Whereas neither Y175E norY175S mutant HA-Cyclin T1 did. Binding of CycT1 to
Tat enhances its affinity to TAR in an in vitro assay
[36]. Consistently, we found that while Cyclin T1- wild
type efficiently bound to HIV TAR, the Y175E and
Y175S mutants did not (Figure 6C). Furthermore, Tat
also binds 7SK snRNA [37]. Similarly, while CycT1-
wild type associated with 7SK snRNA, the Y175E and
Y175S mutants did not.
Taken together these data indicate that tyrosine Y175
is critical for both Hexim1 and Tat binding. As a result,
the mutant proteins cannot associate with TAR and
support Tat-dependent activation of an HIV LTR reporter
plasmid.
Discussion
We have found several point mutations in the Cyclin T1
CBD that impaired P-TEFb/Hexim1/7SK snRNP com-
plex assembly. A two-hybrid screen following random
and targeted mutagenesis generated several single
amino-acid changes in Cyclin T1 that impaired its
binding to Hexim1 (Figure 1A and B). However, out of
the 15 mutants impaired for Hexim1 binding in the
yeast 2-hybrid, only 4 (L133P, K168E, Y175E and
Y175S) were found deficient when expressed in human
cells. Some important post-translational modifications
might be missing in yeast cells or alternatively, isolated
Cyclin T1 in the 2-hybrid system might be more sensi-
tive to mutations than Cyclin T1 bound to its partner
Figure 4 Two-hybrid assay of nematode Hexim interactions with Cyclin T. (A) Yeast cells transformed with plasmids expressing wild-type or
mutant C.elegans Hexim (ceHexim) and Cyclin T (cit-1.2) fused to the Gal4 DNA-binding and Gal4 activation domains, respectively, grew in LT
medium. Ura3 expression induced by interaction between partners is required for growth in LTU medium (lacking uracil). (B) Like in A but using
human Hexim1 and Cyclin T1 fusion proteins.
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binding of Hexim1 to Cdk9 might stabilize its inter-
action with Cyclin T1. A Cyclin T1 mutant resulting from
four substitutions and a deletion, CycT1-U7, had been
previously described as unable to bind either Cdk9 or
Hexim1 [38]. The Y175 mutations, the Y175E one in
particular, showed the sharpest Hexim1 binding defi-
ciency in human cells. It is the first single mutant Cyclin
T1 protein reported with strong Hexim1 binding defi-
ciency that still retains normal capacity to bind Cdk9 and
displays P-TEFb activity in vivo.An unstructured Hexim1 peptide located N-terminal to
alpha-1 helix is essential for Cyclin T1 binding
We found that replacement of the aromatic F262, F267
and H275 Hexim1 residues by aliphatic apolar amino-
acids severely impairs human Hexim1 binding to P-TEFb
in a two hybrid assay (this work) or immunoprecipitation
from human cell lysates (data not shown). The structural
importance of phenylalanine F267 is strengthened by its
conservation throughout evolution (Figure 3B). A muta-
tion of the corresponding residue in the very distant C.
elegans Hexim protein homologue also prevented Hexim/Cyclin T interaction. Human Hexim1 F262 and F267
residues belong to an unstructured peptide according to
predictions and NMR data [23]. Of particular interest,
p21Cip1 and p27Kip1 cell-cycle CDK inhibitors [39] as well
as the HIV-1 Tat protein, a P-TEFb activator, are also
largely unstructured before binding their target [39-41].
The critical involvement of an unfolded domain that
appears to be similarly involved in Cyclin T1 recognition
by Hexim1, might emerge as a common feature in Cyclin
dependent kinase regulation.Hexim1 likely binds Cyclin T1 in the groove between the
two Cyclin folds
Although they were generated randomly, Cyclin T1
amino-acid mutations leading to Hexim1 binding defi-
ciency in the two-hybrid assay were clearly not distributed
at random when positioned on the 3-D structure of human
Cdk9/Cyclin T1 (Figure 2A-D). The Cyclin Box Domain of
Cyclin T1 comprises two canonical “cyclin folds” each con-
sisting of five helices [21]. Although Cyclin T1 contacts
Cdk9 through residues in the N-terminal cyclin fold, many
residues leading to both Hexim1 and Cdk9 binding defi-
ciency were found in the C-terminal cyclin fold (Figure 1B).
Figure 5 Functional characterization of Cyclin T1 mutant proteins expressed in human cells. (A) Coimmunoprecipitation of Cdk9 and Hexim1
with Gal4-CycT1 proteins. Mutants in red are reproducibly deficient for Hexim1 binding. Gal4-CycT1 mutant proteins were transiently expressed in
HEK293 cells. Immunoprecipitation was performed with anti-Gal4 antibodies. Immunoprecipitated proteins were detected on Western blot with Cdk9,
Cyclin T1 and Hexim1 antibodies. (B) CTD kinase assay associated with immunoprecipitated Gal4-CycT1 proteins. (Left) Incorporation of 32PO4 in a
CTD4 peptide increases with incubation time (min.). (Right) Western blots showing that immunoprecipitates used for kinase assays contained the same
quantities of Cdk9 and Gal4-CycT1 proteins. (C) In vivo assays of P-TEFb activity. Expression of a luciferase reporter gene driven by 5 Gal4 UAS upstream
a minimal HIV promoter is activated by cotransfected Gal4-CycT1 proteins in HEK 293T cells. Fold transactivations are relative to luciferase activity in
cells that do not express Gal4-Cyclin T1 proteins. Data result from three independent experiments with standard error bars. Western blots show
proteins detected in lysates of typical experiments using an anti Cyclin T1 antibody. Gal4-Cyclin T1 migrates above the endogenous Cyclin T1.
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binding impairment was exposed to the solvent, suggesting
that these mutations might as well have a negative impact
on the overall folding of the Cyclin T1 helices and that theconformation of the C-terminal Cyclin fold impacts the
conformation of the N-terminal cyclin fold.
Several (Hexim1 (−), Cdk9 (+++)) mutated residues were
found on the surface, exposed to the solvent. They were
Figure 6 Y175 Mutations in Cyclin T1 impair binding to 7SK snRNA, HIV TAR and Tat. (A) CycT1-Y175 mutations abolish Tat transactivation in
murine cells - 3T3 murine cells were co-transfected with the Myc-Tat, HA-CycT1 (wild type or Y175 mutant human Cyclin T1 proteins), HIV-LTR-Photinus luciferase
and a Renilla luciferase reporter. 48 hr after transfection, luciferase activity was monitored. Photinus luciferase readings were normalized to Renilla expression. Fold
transactivation are relative to luciferase activity in the absence of both Tat and human Cyclin T1. Rescue of Tat transactivation by wild-type Cyclin T1 was set to
100. Results are representative of the mean value of triplicate wells; error bars show±SEM. Lower panel shows expression levels of HA-Cyclin T1 in the experi-
ment. (B) Impaired association of Cyclin T1-Y175 mutants with HIV Tat. 293T cells were co-transfected with HA-Tagged CycT1-wild type or Y175 mutated,
Flag-Tat and GFP expressing plasmids to control transfection efficiency. HA-Cyclin T1 proteins were precipitated with α-HA antibody, separated on
SDS-PAGE and analyzed by Western blot with antibodies against their epitope Tags. (C) Impaired association of Cyclin T1-Y175 mutants with
TAR and 7SK snRNA. 293T cells were transfected with the HIV-LTR-BFP provirus (generating TAR RNA and Tat) and with the indicated HA-Cyclin T1
wild type or mutants. 48 h post transfection RNAs were coimmunoprecipitated with α-HA (■) or non-immune (□) rabbit antibodies and analyzed by
RTqPCR using primers specific to either 7SK snRNA or HIV TAR. The signal obtained from RNAs immunoprecipitated in the absence of co-transfected
HA-Cyclin T1 was set to 1.
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(Figure 2A-D), likely defining a contact interface between
Hexim1 and Cyclin T1. The other residues impairing
Hexim1 binding were either (i) in the vicinity of other
solvent-exposed residues identified in the screen, suggest-
ing that they could correctly orientate the Hexim1-binding
amino-acids at the surface or (ii) positioned and oriented
within helical interfaces inside the cyclin box, suggestingthat their mutations had major effects on the overall main-
tenance of the Cyclin T1 stability or dynamics.
Cyclin T1 Y175 at the tip of a hydrogen-bond network
connecting both cyclin folds
Tyrosine Y175 was found to be the most critical residue
for Hexim1 binding in human cells. It is located at the
tip of hydrogen-bond network linking the two cyclin
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crystals obtained in the presence of DRB [42] or flavopiri-
dol [21] (Additional file 1: Figure S1). It is close to H154
and T179 that also came out in the screen (Figure 2G
and H). The six aromatic carbon atoms forming the
aromatic ring of Y175 are located at an average distance
of 4 Å from carbon atom 5 of the imidazole ring of
histidine H154. Such distance and relative orientations
are consistent with a Pi hydrogen bond [43] linking the
carbon 5 of H154 to the aromatic ring of Y175 (Figure 2H).
Supporting the importance of the H154 to Y175 Pi-bond,
a targeted replacement of Y175 by a serine (Y175S) lack-
ing a side-chain aromatic ring also provided a strong
Hexim1 binding deficiency phenotype. The 3-D structure
further suggests that H154 is itself engaged in a Pi-bond
with the side-chain amide hydrogen of asparagine N60
and engages a conventional hydrogen bond with the
side-chain oxygen of threonine T179 (Figure 2H). N60
further engages a hydrogen bond with Q56. Q56 also
engages hydrogen bonds with Q50 and Q46. Mutations
of T179, H154, N60, Q56 and Q50 all came out in the
screen. N60, Q56, Q50 or Q46 were next replaced by
targeted mutagenesis with residues with aliphatic side-
chains. Such replacements suppress H-bonds without
introducing charges that might have lead to major con-
formational changes. The resulting mutant proteins
also lost the capacity to interact with Hexim1 and yet
retained full capacity to interact with Cdk9. Furthermore,
the I59F mutation that introduces a bulky residue next to
N60 came out twice in the screen. It might have affected
the positioning of N60 thus preventing it to form appro-
priate hydrogen bonds. This network is important for
Hexim1 but not for Cdk9 binding as 7 out of its 8 residues
came out in our screen. Thus, tyrosine Y175 is at the
tip of a hydrogen bond network involving 8 residues
holding together four helices. Helices (H1, H2) belong
to the N-terminal whereas helices (H1′, H2′) belong to
the C-terminal cyclin fold (Figure 2G). Rigidity of the
cyclin box might be important for Hexim1 binding.
Overlap between Hexim1 and HIV-1 Tat binding
interfaces on Cyclin T1
The structure of complexes formed by Cyclin T1 and
some of its partners have been solved by X-ray crystal-
lography. The putative Hexim binding surface does not
overlap the Cyclin T1 contact surface with the AFF4
subunit of the Super Elongator Complex (SEC) [44,45].
In contrast, the same groove in Cyclin T1 that is between
the cyclin folds where Y175 is positioned, is important for
binding of P-TEFb to Tat [22] or to Hexim1 (Figure 2E
and F). We also identified two residues (K168 and D169)
that were impaired for Hexim1 binding, but appear off
limits to the Tat and AFF4 binding surfaces. The Q46 and
Q50 Cyclin T1 residues that belong to the Y175 H-bondnetwork are also likely involved in Cyclin T1 binding to
Tat. Replacing these residues as well as F176 (located next
to Y175) by alanines impaired Tat activation [46]. The
overlap between Tat and Hexim1 interfaces on Cyclin T1
accounts for their mutually exclusive binding [7,10]. The
Tat Proline P3 nitrogen belonging to the peptide bond
also forms a Pi-bond with Y175 (Figure 2I). The deficient
binding of Tat to both the Y175E and Y175S Cyclin T1
mutants supports an important contribution of this Pi-
bond in Cyclin T1 binding to Tat. As a possible conse-
quence, the Cyclin T1 Y175E and Y175S mutant proteins
are deficient in supporting HIV LTR transactivation by Tat.
Conclusion
To summarize, an extensive mutagenesis of both Hexim1
and Cyclin T1 provided insight into how these proteins
interact with each other. Our findings illustrate the power
of genetics in mapping interfaces in protein-protein inter-
actions [26]. Cyclin T1 mutations impairing Hexim1 bind-
ing were found to be clustered on the Cyclin T1 surface
overlapping with the HIV-1 Tat protein contact surface
[22], thus accounting for Hexim1 and Tat mutual exclu-
sive binding to Cyclin T1. Furthermore, the interaction
characteristics of C.elegans protein homologues in a two-
hybrid assay supported the existence of a functional
Hexim homologue in nematodes. Overall, it generated
attractive point mutations that retained P-TEFb activity
and will be useful to functionally characterize the import-
ance of specific Cyclin T1 interactions in live cells.
Methods
Plasmids
The ampicillin resistance gene in pASΔΔ [47] was replaced
by the kanamycin resistance gene by the mini-λ-Red re-
combination method [48] in NM1100 bacteria (MG1655
mini-λ tet – from Dr. Nadim Madjalani) to provide pASK,
a 2 μ yeast vector coding for the TRP1 gene and the GAL4
binding domain. pACT2-Hexim1(181–359) and pACT2-
CDK9 were 2 μ yeast plasmids comprising the LEU2
gene and the GAL4 activation domain fused to Hexim1
C-terminal domain or Cdk9 [7]. The Hexim1 cDNA was
cloned into pAdRSV-Flag vector as described [7]. An arti-
ficial human Cyclin T1 cDNA (CycT1m) was synthesized
(Genscript) using the degeneracy of the genetic code
introducing many unique restriction sites at convenient
positions for genetic engineering. The full-length Cyclin
T1m cDNA was cloned between Msc1/BamH1 in pASK
to provide pASK-CycT1m comprising the TRP1 gene and
the GAL4 DNA binding domain fused to CycT1m. The
same sequence was cloned between BspE1/BamH1 in
the pEGFP-C1 (ClonTech) expression vector to provide
pEGFPC1-CycT1m. The Gal4 DNA binding domain was
inserted between AfeI/EcoRI from pEGFPC1-CycT1m to
provide pCMVGal4-CycT1m. HA-Tagged wild type or
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were cloned into pHAGE-CMV-IRES-puromycin lenti-
vector between NotI/BamH1 restriction sites to provide
pHAGE-HA-CycT1 plasmids. pG5-38-HIV-Luc derives
from pG5-38-HIV-CAT [33]. pHIV-LTR-Luc (Photinus
Luciferase) reporter, pCDNA3-Flag-Tat, pCDNA3-Myc-Tat
and the lentiviral proviral vector expressing LTR-Tat-BFP
have been described previously [38]. pRL Renilla luciferase
reporter plasmid was from Promega.
Yeast two-hybrid assays
MaV103 yeast cells (MATa SPAL10::URA3 leu2-3,112
trp1-901 his3-D200 ade2-101 gal4D gal80D can1r cyh2r
GAL1::HIS3@LYS2 GAL1::lacZ@URA3) lack the genomic
ura3 gene and have an absolute requirement for uracil
in the culture medium [27,47]. However, they have an
inserted ura3 gene copy placed downstream the Gal4
DNA sequences that is activated when a GAL4 DNA
binding domain (GAL4BD) fusion protein binds a GAL4
activation domain (GAL4AD) fusion protein. To per-
form the Hexim1 vs CycT1 interaction assay, Hexim1
C-terminal domain (Hexim1 181–359) and CycT1 coding
sequences were fused to GAL4AD and GAL4BD respect-
ively. A positive interaction permits growth on media
lacking uracil. As URA3 converts 5-fluoroorotic acid
(5-FOA) into a toxic metabolite [27], a positive inter-
action results in cell death if 5-FOA is added to the
medium.
Cyclin T1 mutant selection
Fragments of the Cyclin T1 Cyclin Box Domain (CBD)
were amplified by 30 cycles of error-prone PCR using
Taq polymerase (InVitroGen), 100 ng pASK-CycT1m
template, 0.4 mM primers, 7 mM Mg2+, 0.25 mM Mn2+,
1 mM dCTP and dTTP, 0.2 mM dATP and dGTP in
100 μl final volume. Plasmid pASK-CycT1m (suppressing
tryptophan auxotrophy and coding for the entire Cyclin
T1 protein) was digested within the CBD sequence by
two restriction enzymes and the resulting linearized
vector was isolated from an agarose gel. MaV103 strain
was transformed first with pACT2-Hexim1(181–359)
(suppressing leucine auxotrophy) and grown on SC
medium lacking leucine. The resulting cells were further
transformed with 1 μg of linearized pASK-CycT1m and
3 μg of purified randomly mutagenized PCR product. The
PCR product and the gapped plasmid overlapped over
50 nt on both sides allowing homologous recombination.
Transformants were plated on SC medium lacking trypto-
phane, leucine and uracil (MP biomedical) supplemented
with 20 g.l−1 uracil and 1.5 g.l−1 FOA (stock solution
100 g.l−1 in DMSO). FOA resistant colonies were har-
vested after 10 days of growth at 30°C. The CBD coding
sequence was amplified by high-fidelity PCR from isolated
colonies lysed in 0.07 M NaOH for 10 minutes at 99°C,using primers flanking the CBD and Phusion polymerase
(Finnzyme). The PCR products were sequenced and
recloned after EcoRI and AflII restriction into pASK-
CycT1m and pCMVGal4-CycT1m.Cell culture, transfections, co-immunoprecipitation, kinase
and luciferase assays
3T3 or HEK 293 cells were cultured in Dulbecco’s Modi-
fied Eagle’s Media supplemented with 10% Fetal Calf
Serum. They were either transfected using LyoVec (Invivo-
Gen) or Lipofectamine 2000 (Life Technologies). 48 h after
transfection, cells were lysed in 10 mM Hepes pH7.9,
10 mM KCl, 200 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, supplemented with 1 mM dithiothreitol, 40 units.
ml−1 RNasin (Promega), protease inhibitor mixture (P-
8340; Sigma), 1 mM phenylmethylsulfonyl fluoride, 0.5%
Igepal (SIGMA). Proteins were detected with anti-Cyclin
T1 (Santa Cruz sc-8127), anti-Cdk9 (Santa Cruz sc-484),
anti-Gal4 (Santa Cruz sc-510) or C4 anti-Hexim1 [7].
Tagged proteins were immunoprecipitated with protein A
agarose beads. Western blot were imaged with a LAS 4000
CCD camera system (GE Healthcare). For kinase assays,
agarose beads after immunoprecipitation were split in two
batches, one was analyzed by Western blot, the other one
was incubated at room temperature with (YSPTSPS)4 pep-
tide (1 μg per assay) and ATP (100 nM, 0.1 μCi per assay).
The reaction was arrested at various times by addition of
SDS loading buffer. The phosphorylated peptide was sepa-
rated by SDS PAGE. The gel was autoradiographed and
quantified. For luciferase assays, cells were lysed 48 hr
after transfection and both Photinus and Renilla luciferase
activities were determined following the supplier’s recom-
mended procedures (Promega).RNA co-immunoprecipitation with mutated Cyclin T1
HEK293T cells were transfected with pHAGE-HA-CycT1wt
or mutant, pHIV-LTR-Luc and pCDNA-Myc-Tat. pCMV-
GFP was added as a transfection efficiency control (90% cells
were green after 48 hrs). 48 hr post transfection cells were
lysed in 0.5% NP-40; 20 mM HEPES pH 7.8; 100 mM KCl;
0.2 mM EDTA; protease inhibitor cocktail (Sigma); RNAse
inhibitor (New England Biolabs). Clarified cell lysates were
incubated overnight either with anti-HA antibody (Abcam -
ab-9110) or control anti-human IgG. Protein A-Sepharose
beads were pre-blocked with bovine serum albumin and
yeast tRNA for 2 hr at 4°C. After immunoprecipitation,
input samples and the beads were extracted with Tris-
Phenol and chloroform followed by ethanol precipita-
tion. cDNAs were made from RNAs using cDNA high
capacity kit (Applied Bio-system). Real time PCR used
KAPA SYBER GREEN fast mix and TAR or 7SK spe-
cific primers.
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Additional file 1: Figure S1. Alternate positions of Y175. (A)
Comparison between P.TEFb.ATP (pdb3blq) (grey) and P-TEFb.flavopiridol
(pdb3blr) (colour). (B) Comparison between P.TEFb.ATP (pdb3blq) (grey)
and P-TEFb.DRB (pdb3blr) (colour). Y175(red) in pdb3blq rotates by 90° in
pdb3blr and pdb3MY1 (pink).
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